1. Home
  2. RYTM vs DUOL Comparison

RYTM vs DUOL Comparison

Compare RYTM & DUOL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Rhythm Pharmaceuticals Inc.

RYTM

Rhythm Pharmaceuticals Inc.

HOLD

Current Price

$115.63

Market Cap

5.8B

Sector

Health Care

ML Signal

HOLD

Logo Duolingo Inc.

DUOL

Duolingo Inc.

HOLD

Current Price

$130.90

Market Cap

5.9B

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
RYTM
DUOL
Founded
2008
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Computer Software: Prepackaged Software
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
5.8B
5.9B
IPO Year
2017
2021

Fundamental Metrics

Financial Performance
Metric
RYTM
DUOL
Price
$115.63
$130.90
Analyst Decision
Strong Buy
Buy
Analyst Count
14
18
Target Price
$131.14
$176.69
AVG Volume (30 Days)
640.7K
1.1M
Earning Date
05-05-2026
05-04-2026
Dividend Yield
N/A
N/A
EPS Growth
28.34
355.85
EPS
N/A
1.53
Revenue
N/A
$1,037,589,000.00
Revenue This Year
$55.34
$18.93
Revenue Next Year
$86.06
$14.02
P/E Ratio
N/A
$80.12
Revenue Growth
N/A
38.71
52 Week Low
$74.50
$87.89
52 Week High
$122.20
$373.50

Technical Indicators

Market Signals
Indicator
RYTM
DUOL
Relative Strength Index (RSI) 60.52 44.04
Support Level $98.76 $107.24
Resistance Level $113.03 $138.41
Average True Range (ATR) 4.84 8.06
MACD 0.15 -0.62
Stochastic Oscillator 98.64 33.23

Price Performance

Historical Comparison
RYTM
DUOL

About RYTM Rhythm Pharmaceuticals Inc.

Rhythm Pharmaceuticals Inc is a commercial-stage biopharmaceutical company engaged in the development and commercialization of therapies for patients with rare neuroendocrine diseases. The company is focused on advancing its melanocortin-4 receptor (MC4R) agonists, including its main asset, IMCIVREE (setmelanotide), as a precision medicine designed to treat hyperphagia and severe obesity caused by rare MC4R pathway diseases. In addition, it has two early-stage investigational MC4R agonists in clinical development, RM-718 and bivamelagon, designed not to cause hyperpigmentation. The company is also focused on advancing potential candidates for congenital hyperinsulinism. It currently operates in two business segments: the United States, which generates maximum revenue, and International.

About DUOL Duolingo Inc.

Duolingo Inc is a technology company that develops a mobile learning platform to learn languages. Its products are powered by sophisticated data analytics and artificial intelligence and delivered with class art, animation, and design to make it easier for learners to stay motivated, master new material, and achieve their learning goals. Its solutions include the Duolingo Language Learning App, Super Duolingo, Duolingo English Test: AI-Driven Language Assessment, Duolingo For Schools, Duolingo ABC, and Duolingo Math. It has four predominant sources of revenue: time-based subscriptions, in-app advertising placement by third parties, the Duolingo English Test, and In-App purchases. Geographically, the company generates revenue from its customers in the United States and other markets.

Share on Social Networks: